Teva- Pharmaceutical Industries Other Current Liabilities

As of the most recent data (June 2026), TEVA shows a other current liabilities of $8.4B. That compares with $6.4B in the prior-year period — up 31.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TEVA's other current liabilities is now $8.4B (was $6.4B) — a 31.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Teva- Pharmaceutical Industries is outperforming or lagging.

Tracking TEVA's other current liabilities over time shows whether Teva- Pharmaceutical Industries is scaling, shrinking, or reshaping that part of the business. The current reading is $8.4B That compares with $6.4B in the prior-year period — up 31.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Teva- Pharmaceutical Industries's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $8.4B) with ownership activity and broader fundamentals.

Teva- Pharmaceutical Industries's other current liabilities is $8.4B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.